| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new prognostic and predictive tool for shared decision making in stage III colon cancer
|
Sobrero, Alberto F.
|
|
|
138 |
C |
p. 182-188
|
artikel
|
| 2 |
Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study
|
Yanes, Manar
|
|
|
138 |
C |
p. 80-88
|
artikel
|
| 3 |
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
|
Cardone, Claudia
|
|
|
138 |
C |
p. 1-10
|
artikel
|
| 4 |
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
|
Vandenbroucke, Tineke
|
|
|
138 |
C |
p. 57-67
|
artikel
|
| 5 |
Clinical development of cell therapies for cancer: The regulators' perspective
|
Exley, Andrew R.
|
|
|
138 |
C |
p. 41-53
|
artikel
|
| 6 |
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve
|
Guberina, Nika
|
|
|
138 |
C |
p. 156-168
|
artikel
|
| 7 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results
|
Sinn, M.
|
|
|
138 |
C |
p. 172-181
|
artikel
|
| 8 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)
|
Tsai, Hsiang-Lin
|
|
|
138 |
C |
p. 19-29
|
artikel
|
| 9 |
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019)
|
Clover, A.J.P.
|
|
|
138 |
C |
p. 30-40
|
artikel
|
| 10 |
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment
|
Derksen, Jeroen W.G.
|
|
|
138 |
C |
p. 99-108
|
artikel
|
| 11 |
Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era
|
Vasseur, Loïc
|
|
|
138 |
C |
p. 189-192
|
artikel
|
| 12 |
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
|
Montrone, Michele
|
|
|
138 |
C |
p. 109-112
|
artikel
|
| 13 |
Head and neck mucosal melanoma: The United Kingdom national guidelines
|
Nenclares, Pablo
|
|
|
138 |
C |
p. 11-18
|
artikel
|
| 14 |
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases
|
Boilève, Alice
|
|
|
138 |
C |
p. 89-98
|
artikel
|
| 15 |
High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!
|
van Dam, Peter A.
|
|
|
138 |
C |
p. 225-227
|
artikel
|
| 16 |
Immune checkpoint inhibitor–induced bullous pemphigoid: Towards a new class of drug-drug interaction?
|
Pujalte-Martin, Marc
|
|
|
138 |
C |
p. 122-124
|
artikel
|
| 17 |
Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
|
Kähler, Katharina C.
|
|
|
138 |
C |
p. 169-171
|
artikel
|
| 18 |
Intention-to-treat analysis in precision oncology: A cautious interpretation
|
Garg, Pankaj K.
|
|
|
138 |
C |
p. 229-231
|
artikel
|
| 19 |
Letter responds to comment on “intention-to-treat analysis in precision oncology: A cautious interpretation”
|
Sicklick, Jason
|
|
|
138 |
C |
p. 228
|
artikel
|
| 20 |
Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’
|
Diekstra, Meta H.M.
|
|
|
138 |
C |
p. 54-56
|
artikel
|
| 21 |
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
|
Salzmann, Martin
|
|
|
138 |
C |
p. 125-132
|
artikel
|
| 22 |
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
|
Liu, Shiliang
|
|
|
138 |
C |
p. 113-121
|
artikel
|
| 23 |
Response to the letter commenting on ʻEffect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic reviewʼ
|
Jansen, Erik E.L.
|
|
|
138 |
C |
p. 232-233
|
artikel
|
| 24 |
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications
|
Lee, Karla A.
|
|
|
138 |
C |
p. 149-155
|
artikel
|
| 25 |
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
|
Loriot, Yohann
|
|
|
138 |
C |
p. 202-211
|
artikel
|
| 26 |
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non–small cell lung cancer: IFCT-1201 MODEL trial
|
Quoix, Elisabeth
|
|
|
138 |
C |
p. 193-201
|
artikel
|
| 27 |
The association between fertility treatments and the incidence of paediatric cancer: A systematic review and meta-analysis
|
Zhang, Yaoyao
|
|
|
138 |
C |
p. 133-148
|
artikel
|
| 28 |
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions
|
Gebhardt, Christoffer
|
|
|
138 |
C |
p. 68-76
|
artikel
|
| 29 |
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs
|
Giuliani, Jacopo
|
|
|
138 |
C |
p. 77-79
|
artikel
|
| 30 |
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study
|
Langer, Thorsten
|
|
|
138 |
C |
p. 212-224
|
artikel
|
Tijdschrift beschrijving